ID   CTLA4_HUMAN             Reviewed;         223 AA.
AC   P16410; A0N1S0; E9PDH0; Q0PP65; Q52MC1; Q53TD5; Q5S005; Q8WXJ1;
AC   Q96P43; Q9UKN9;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   10-JAN-2003, sequence version 3.
DT   21-MAR-2012, entry version 139.
DE   RecName: Full=Cytotoxic T-lymphocyte protein 4;
DE   AltName: Full=Cytotoxic T-lymphocyte-associated antigen 4;
DE            Short=CTLA-4;
DE   AltName: CD_antigen=CD152;
DE   Flags: Precursor;
GN   Name=CTLA4; Synonyms=CD152;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE
RP   SPECIFICITY, ALTERNATIVE SPLICING, AND VARIANT ALA-17.
RX   MEDLINE=91318145; PubMed=1713603;
RA   Harper K., Balzano C., Rouvier E., Mattei M.-G., Luciani M.-F.,
RA   Golstein P.;
RT   "CTLA-4 and CD28 activated lymphocyte molecules are closely related in
RT   both mouse and human as to sequence, message expression, gene
RT   structure, and chromosomal location.";
RL   J. Immunol. 147:1037-1044(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=21601151; PubMed=11735222; DOI=10.1006/geno.2001.6655;
RA   Ling V., Wu P.W., Finnerty H.F., Agostino M.J., Graham J.R., Chen S.,
RA   Jussiff J.M., Fisk G.J., Miller C.P., Collins M.;
RT   "Assembly and annotation of human chromosome 2q33 sequence containing
RT   the CD28, CTLA4, and ICOS gene cluster: analysis by computational,
RT   comparative, and microarray approaches.";
RL   Genomics 78:155-168(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), VARIANT ALA-17, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=18595775; DOI=10.1016/j.clim.2008.05.006;
RA   Gu M., Kakoulidou M., Giscombe R., Pirskanen R., Lefvert A.K.,
RA   Klareskog L., Wang X.;
RT   "Identification of CTLA-4 isoforms produced by alternative splicing
RT   and their association with myasthenia gravis.";
RL   Clin. Immunol. 128:374-381(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wu P.W., Ling V.;
RT   "Full length sequence of hCTLA4 cDNA.";
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-223.
RC   TISSUE=Lymphocyte;
RX   MEDLINE=89120925; PubMed=3220103; DOI=10.1002/eji.1830181206;
RA   Dariavach P., Mattei M.-G., Golstein P., Lefranc M.-P.;
RT   "Human Ig superfamily CTLA-4 gene: chromosomal localization and
RT   identity of protein sequence between murine and human CTLA-4
RT   cytoplasmic domains.";
RL   Eur. J. Immunol. 18:1901-1905(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-223, AND TISSUE SPECIFICITY.
RX   MEDLINE=99425274; PubMed=10493833; DOI=10.1006/geno.1999.5930;
RA   Ling V., Wu P.W., Finnerty H.F., Sharpe A.H., Gray G.S., Collins M.;
RT   "Complete sequence determination of the mouse and human CTLA4 gene
RT   loci: cross-species DNA sequence similarity beyond exon borders.";
RL   Genomics 60:341-355(1999).
RN   [10]
RP   FUNCTION.
RX   MEDLINE=91341416; PubMed=1714933; DOI=10.1084/jem.174.3.561;
RA   Linsley P.S., Brady W., Urnes M., Griosmaire L.S., Damle N.K.,
RA   Ledbetter J.A.;
RT   "CTLA-4 is a second receptor for the B cell activation antigen B7.";
RL   J. Exp. Med. 174:561-569(1991).
RN   [11]
RP   PHOSPHORYLATION AT TYR-201.
RX   PubMed=9175836; DOI=10.1016/S1074-7613(00)80346-5;
RA   Shiratori T., Miyatake S., Ohno H., Nakaseko C., Isono K.,
RA   Bonifacino J.S., Saito T.;
RT   "Tyrosine phosphorylation controls internalization of CTLA-4 by
RT   regulating its interaction with clathrin-associated adaptor complex
RT   AP-2.";
RL   Immunity 6:583-589(1997).
RN   [12]
RP   PHOSPHORYLATION AT TYR-201.
RX   PubMed=9813138; DOI=10.1006/bbrc.1998.9559;
RA   Schneider H., Schwartzberg P.L., Rudd C.E.;
RT   "Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and
RT   regulates PI 3-kinase binding to T-cell antigen CTLA-4.";
RL   Biochem. Biophys. Res. Commun. 252:14-19(1998).
RN   [13]
RP   POLYMORPHISM.
RX   PubMed=12724780; DOI=10.1038/nature01621;
RA   Ueda H., Howson J.M., Esposito L., Heward J., Snook H.,
RA   Chamberlain G., Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G.,
RA   Herr M.H., Dahlman I., Payne F., Smyth D., Lowe C., Twells R.C.,
RA   Howlett S., Healy B., Nutland S., Rance H.E., Everett V., Smink L.J.,
RA   Lam A.C., Cordell H.J., Walker N.M., Bordin C., Hulme J., Motzo C.,
RA   Cucca F., Hess J.F., Metzker M.L., Rogers J., Gregory S.,
RA   Allahabadia A., Nithiyananthan R., Tuomilehto-Wolf E., Tuomilehto J.,
RA   Bingley P., Gillespie K.M., Undlien D.E., Ronningen K.S., Guja C.,
RA   Ionescu-Tirgoviste C., Savage D.A., Maxwell A.P., Carson D.J.,
RA   Patterson C.C., Franklyn J.A., Clayton D.G., Peterson L.B.,
RA   Wicker L.S., Todd J.A., Gough S.C.;
RT   "Association of the T-cell regulatory gene CTLA4 with susceptibility
RT   to autoimmune disease.";
RL   Nature 423:506-511(2003).
RN   [14]
RP   GLYCOSYLATION AT ASN-113 AND ASN-145.
RX   PubMed=16002699;
RA   Darlington P.J., Kirchhof M.G., Criado G., Sondhi J., Madrenas J.;
RT   "Hierarchical regulation of CTLA-4 dimer-based lattice formation and
RT   its biological relevance for T cell inactivation.";
RL   J. Immunol. 175:996-1004(2005).
RN   [15]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16551244; DOI=10.1146/annurev.immunol.24.021605.090535;
RA   Teft W.A., Kirchhof M.G., Madrenas J.;
RT   "A molecular perspective of CTLA-4 function.";
RL   Annu. Rev. Immunol. 24:65-97(2006).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18468488; DOI=10.1016/j.it.2008.02.011;
RA   Valk E., Rudd C.E., Schneider H.;
RT   "CTLA-4 trafficking and surface expression.";
RL   Trends Immunol. 29:272-279(2008).
RN   [17]
RP   PHARMACEUTICAL.
RX   PubMed=19426230; DOI=10.1111/j.1600-065X.2009.00780.x;
RA   Linsley P.S., Nadler S.G.;
RT   "The clinical utility of inhibiting CD28-mediated costimulation.";
RL   Immunol. Rev. 229:307-321(2009).
RN   [18]
RP   STRUCTURE BY NMR OF 37-165.
RX   MEDLINE=97372889; PubMed=9228944; DOI=10.1038/nsb0797-527;
RA   Metzler W.J., Bajorath J., Fenderson W., Shaw S.Y., Constantine K.L.,
RA   Naemura J., Leytze G., Peach R.J., Lavoie T.B., Mueller L.,
RA   Linsley P.S.;
RT   "Solution structure of human CTLA-4 and delineation of a CD80/CD86
RT   binding site conserved in CD28.";
RL   Nat. Struct. Biol. 4:527-531(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD86,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=11279501; DOI=10.1038/35069112;
RA   Schwartz J.C., Zhang X., Fedorov A.A., Nathenson S.G., Almo S.C.;
RT   "Structural basis for co-stimulation by the human CTLA-4/B7-2
RT   complex.";
RL   Nature 410:604-608(2001).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 36-161, GLYCOSYLATION AT
RP   ASN-113, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=21156796; DOI=10.1074/jbc.M110.182394;
RA   Yu C., Sonnen A.F., George R., Dessailly B.H., Stagg L.J., Evans E.J.,
RA   Orengo C.A., Stuart D.I., Ladbury J.E., Ikemizu S., Gilbert R.J.,
RA   Davis S.J.;
RT   "Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4
RT   (CTLA-4) receptor triggering.";
RL   J. Biol. Chem. 286:6685-6696(2011).
RN   [21]
RP   VARIANT ALA-17, AND INVOLVEMENT IN IDDM12.
RX   MEDLINE=97402209; PubMed=9259273; DOI=10.1093/hmg/6.8.1275;
RA   Marron M.P., Raffel L.J., Garchon H.-J., Jacob C.O., Serrano-Rios M.,
RA   Martinez Larrad M.T., Teng W.-P., Park Y., Zhang Z.-X.,
RA   Goldstein D.R., Tao Y.-W., Beaurain G., Bach J.-F., Huang H.-S.,
RA   Luo D.-F., Zeidler A., Rotter J.I., Yang M.C.K., Modilevsky T.,
RA   Maclaren N.K., She J.-X.;
RT   "Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4
RT   polymorphisms in multiple ethnic groups.";
RL   Hum. Mol. Genet. 6:1275-1282(1997).
RN   [22]
RP   POLYMORPHISM, AND INVOLVEMENT IN CELIAC3.
RX   MEDLINE=99205840; PubMed=10189842;
RA   Djilali-Saiah I., Schmitz J., Harfouch-Hammoud E., Mougenot J.-F.,
RA   Bach J.-F., Caillat-Zucman S.;
RT   "CTLA-4 gene polymorphism is associated with predisposition to coeliac
RT   disease.";
RL   Gut 43:187-189(1998).
RN   [23]
RP   VARIANT ALA-17, AND INVOLVEMENT IN THYROID ASSOCIATED ORBITOPATHY.
RX   MEDLINE=99402177; PubMed=10475192; DOI=10.1016/S0140-6736(99)01465-8;
RA   Vaidya B., Imrie H., Perros P., Dickinson J., McCarthy M.I.,
RA   Kendall-Taylor P., Pearce S.H.S.;
RT   "Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers
RT   susceptibility to thyroid associated orbitopathy.";
RL   Lancet 354:743-744(1999).
RN   [24]
RP   VARIANT ALA-17, AND INVOLVEMENT IN GRAVES DISEASE.
RX   MEDLINE=20385252; PubMed=10924276; DOI=10.1006/mgme.2000.3007;
RA   Chistyakov D.A., Savost'anov K.V., Turakulov R.I., Petunina N.A.,
RA   Trukhina L.V., Kudinova A.V., Balabolkin M.I., Nosikov V.V.;
RT   "Complex association analysis of Graves disease using a set of
RT   polymorphic markers.";
RL   Mol. Genet. Metab. 70:214-218(2000).
RN   [25]
RP   VARIANT ALA-17.
RX   MEDLINE=20395844; PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by
RT   mutations in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [26]
RP   INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
RX   PubMed=15138458; DOI=10.1038/sj.ejhg.5201214;
RA   Barreto M., Santos E., Ferreira R., Fesel C., Fontes M.F., Pereira C.,
RA   Martins B., Andreia R., Viana J.F., Crespo F., Vasconcelos C.,
RA   Ferreira C., Vicente A.M.;
RT   "Evidence for CTLA4 as a susceptibility gene for systemic lupus
RT   erythematosus.";
RL   Eur. J. Hum. Genet. 12:620-626(2004).
RN   [27]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO HBV INFECTION, AND VARIANT ALA-17.
RX   PubMed=15452244; DOI=10.1128/JVI.78.20.11258-11262.2004;
RA   Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A.,
RA   Vlahov D., O'Brien S.J., Astemborski J., Thomas D.L.;
RT   "Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B
RT   virus infection.";
RL   J. Virol. 78:11258-11262(2004).
RN   [28]
RP   INVOLVEMENT IN CELIAC3.
RX   PubMed=15657618; DOI=10.1038/sj.ejhg.5201357;
RA   Hunt K.A., McGovern D.P.B., Kumar P.J., Ghosh S., Travis S.P.L.,
RA   Walters J.R.F., Jewell D.P., Playford R.J., van Heel D.A.;
RT   "A common CTLA4 haplotype associated with coeliac disease.";
RL   Eur. J. Hum. Genet. 13:440-444(2005).
RN   [29]
RP   INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS.
RX   PubMed=15688186; DOI=10.1007/s00439-004-1244-1;
RA   Lee Y.H., Harley J.B., Nath S.K.;
RT   "CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-
RT   analysis.";
RL   Hum. Genet. 116:361-367(2005).
CC   -!- FUNCTION: Inhibitory receptor acting as a major negative regulator
CC       of T-cell responses. The affinity of CTLA4 for its natural B7
CC       family ligands, CD80 and CD86, is considerably stronger than the
CC       affinity of their cognate stimulatory coreceptor CD28.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Binds to CD80/B7-1 and
CC       CD86/B7.2.
CC   -!- INTERACTION:
CC       P33681:CD80; NbExp=3; IntAct=EBI-1030991, EBI-1031024;
CC       P42081:CD86; NbExp=2; IntAct=EBI-1030991, EBI-1030956;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Note=Exists primarily an intracellular antigen whose
CC       surface expression is tightly regulated by restricted trafficking
CC       to the cell surface and rapid internalisation;.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P16410-1; Sequence=Displayed;
CC       Name=2; Synonyms=ss-CTLA-4;
CC         IsoId=P16410-2; Sequence=VSP_041284;
CC       Name=3;
CC         IsoId=P16410-3; Sequence=VSP_041284, VSP_041287;
CC       Name=4;
CC         IsoId=P16410-4; Sequence=VSP_041285, VSP_041286, VSP_041287;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in
CC       lymphoid tissues. Detected in activated T-cells where expression
CC       levels are 30- to 50-fold less than CD28, the stimulatory
CC       coreceptor, on the cell surface following activation.
CC   -!- PTM: N-glycosylation is important for dimerization.
CC   -!- PTM: Phosphorylation at Tyr-201 prevents binding to the AP-2
CC       adapter complex, blocks endocytosis, and leads to retention of
CC       CTLA4 on the cell surface.
CC   -!- POLYMORPHISM: Genetic variations in CTLA4 are associated with
CC       susceptibility to several autoimmune disorders. They influence
CC       responsiveness to hepatitis B virus (HBV) infection [MIM:610424].
CC   -!- DISEASE: Genetic variation in CTLA4 influences susceptibility to
CC       systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic,
CC       inflammatory and often febrile multisystemic disorder of
CC       connective tissue. It affects principally the skin, joints,
CC       kidneys and serosal membranes. SLE is thought to represent a
CC       failure of the regulatory mechanisms of the autoimmune system.
CC   -!- DISEASE: Note=Genetic variations in CTLA4 may influence
CC       susceptibility to Graves disease, an autoimmune disorder
CC       associated with overactivity of the thyroid gland and
CC       hyperthyroidism.
CC   -!- DISEASE: Genetic variation in CTLA4 is the cause of susceptibility
CC       to diabetes mellitus insulin-dependent type 12 (IDDM12)
CC       [MIM:601388]. A multifactorial disorder of glucose homeostasis
CC       that is characterized by susceptibility to ketoacidosis in the
CC       absence of insulin therapy. Clinical fetaures are polydipsia,
CC       polyphagia and polyuria which result from hyperglycemia-induced
CC       osmotic diuresis and secondary thirst. These derangements result
CC       in long-term complications that affect the eyes, kidneys, nerves,
CC       and blood vessels.
CC   -!- DISEASE: Genetic variation in CTLA4 is the cause of susceptibility
CC       to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a
CC       multifactorial disorder of the small intestine that is influenced
CC       by both environmental and genetic factors. It is characterized by
CC       malabsorption resulting from inflammatory injury to the mucosa of
CC       the small intestine after the ingestion of wheat gluten or related
CC       rye and barley proteins. In its classic form, celiac disease is
CC       characterized in children by malabsorption and failure to thrive.
CC   -!- PHARMACEUTICAL: Engineered fusion proteins consisting of the
CC       extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig),
CC       inhibit T-cell-dependent antibody responses, and are used as
CC       immunosuppressive agents. They are soluble, have an enhanced
CC       affinity for B7 ligands and act as a competitive inhibitor of
CC       CD28.
CC   -!- SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like)
CC       domain.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CLTA-4 entry;
CC       URL="http://en.wikipedia.org/wiki/CTLA-4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L15006; AAB59385.1; -; mRNA.
DR   EMBL; M74363; AAA52127.1; -; Genomic_DNA.
DR   EMBL; AF411058; AAL40932.1; -; Genomic_DNA.
DR   EMBL; AY792514; AAV66331.1; -; mRNA.
DR   EMBL; AY999702; AAY00166.1; -; mRNA.
DR   EMBL; DQ785106; ABG85285.1; -; mRNA.
DR   EMBL; AF414120; AAL07473.1; -; mRNA.
DR   EMBL; DQ357942; ABC67470.1; -; Genomic_DNA.
DR   EMBL; AC010138; AAX93176.1; -; Genomic_DNA.
DR   EMBL; BC074842; AAH74842.1; -; mRNA.
DR   EMBL; BC074893; AAH74893.1; -; mRNA.
DR   EMBL; M37245; AAA52773.1; -; Genomic_DNA.
DR   EMBL; M37243; AAA52773.1; JOINED; Genomic_DNA.
DR   EMBL; M37244; AAA52773.1; JOINED; Genomic_DNA.
DR   EMBL; AF142144; AAF02499.1; -; Genomic_DNA.
DR   IPI; IPI00028559; -.
DR   IPI; IPI00604432; -.
DR   IPI; IPI00945919; -.
DR   IPI; IPI01018238; -.
DR   PIR; S08614; S08614.
DR   RefSeq; NP_001032720.1; NM_001037631.2.
DR   RefSeq; NP_005205.2; NM_005214.4.
DR   UniGene; Hs.247824; -.
DR   PDB; 1AH1; NMR; -; A=37-161.
DR   PDB; 1H6E; X-ray; 3.60 A; P=197-207.
DR   PDB; 1I85; X-ray; 3.20 A; C/D=36-161.
DR   PDB; 1I8L; X-ray; 3.00 A; C/D=36-161.
DR   PDB; 2X44; X-ray; 2.60 A; D=36-161.
DR   PDB; 3BX7; X-ray; 2.10 A; C=38-161.
DR   PDB; 3OSK; X-ray; 1.80 A; A/B=36-161.
DR   PDBsum; 1AH1; -.
DR   PDBsum; 1H6E; -.
DR   PDBsum; 1I85; -.
DR   PDBsum; 1I8L; -.
DR   PDBsum; 2X44; -.
DR   PDBsum; 3BX7; -.
DR   PDBsum; 3OSK; -.
DR   ProteinModelPortal; P16410; -.
DR   SMR; P16410; 38-160.
DR   IntAct; P16410; 2.
DR   STRING; P16410; -.
DR   PhosphoSite; P16410; -.
DR   DMDM; 27735177; -.
DR   PRIDE; P16410; -.
DR   Ensembl; ENST00000302823; ENSP00000303939; ENSG00000163599.
DR   GeneID; 1493; -.
DR   KEGG; hsa:1493; -.
DR   UCSC; uc002vak.1; human.
DR   CTD; 1493; -.
DR   GeneCards; GC02P204696; -.
DR   H-InvDB; HIX0029846; -.
DR   HGNC; HGNC:2505; CTLA4.
DR   MIM; 109100; phenotype.
DR   MIM; 123890; gene.
DR   MIM; 152700; phenotype.
DR   MIM; 601388; phenotype.
DR   MIM; 609755; phenotype.
DR   MIM; 610424; phenotype.
DR   neXtProt; NX_P16410; -.
DR   Orphanet; 555; Celiac disease.
DR   Orphanet; 855; Hashimoto struma.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   eggNOG; NOG42442; -.
DR   GeneTree; ENSGT00530000063873; -.
DR   HOGENOM; HBG280302; -.
DR   HOVERGEN; HBG057978; -.
DR   InParanoid; P16410; -.
DR   KO; K06538; -.
DR   OMA; SGNKVNL; -.
DR   OrthoDB; EOG4Q58QK; -.
DR   PhylomeDB; P16410; -.
DR   Pathway_Interaction_DB; nfat_tfpathway; Calcineurin-regulated NFAT-dependent transcription in lymphocytes.
DR   Reactome; REACT_6900; Immune System.
DR   DrugBank; DB01281; Abatacept.
DR   NextBio; 6133; -.
DR   ArrayExpress; P16410; -.
DR   Bgee; P16410; -.
DR   CleanEx; HS_CTLA4; -.
DR   Genevestigator; P16410; -.
DR   GermOnline; ENSG00000163599; Homo sapiens.
DR   GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045590; P:negative regulation of regulatory T cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0006974; P:response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   InterPro; IPR008096; CTLA4.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR003596; Ig_V-set_subgr.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 1.
DR   Pfam; PF07686; V-set; 1.
DR   PRINTS; PR01720; CTLANTIGEN4.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Cell membrane;
KW   Complete proteome; Diabetes mellitus; Disulfide bond; Glycoprotein;
KW   Immunity; Immunoglobulin domain; Membrane; Pharmaceutical;
KW   Phosphoprotein; Polymorphism; Reference proteome; Signal;
KW   Systemic lupus erythematosus; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     35       Potential.
FT   CHAIN        36    223       Cytotoxic T-lymphocyte protein 4.
FT                                /FTId=PRO_0000014734.
FT   TOPO_DOM     36    161       Extracellular (Potential).
FT   TRANSMEM    162    182       Helical; (Potential).
FT   TOPO_DOM    183    223       Cytoplasmic (Potential).
FT   DOMAIN       39    140       Ig-like V-type.
FT   REGION       46     50       Homodimerization.
FT   REGION      150    155       Homodimerization.
FT   MOD_RES     201    201       Phosphotyrosine; by TXK.
FT   CARBOHYD    113    113       N-linked (GlcNAc...).
FT   CARBOHYD    145    145       N-linked (GlcNAc...).
FT   DISULFID     58    129
FT   DISULFID     85    103
FT   DISULFID    157    157       Interchain.
FT   VAR_SEQ      38    204       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_041284.
FT   VAR_SEQ      58     58       C -> S (in isoform 4).
FT                                /FTId=VSP_041285.
FT   VAR_SEQ      59    204       Missing (in isoform 4).
FT                                /FTId=VSP_041286.
FT   VAR_SEQ     205    223       PPTEPECEKQFQPYFIPIN -> KEKKPSYNRGLCENAPNR
FT                                ARM (in isoform 3 and isoform 4).
FT                                /FTId=VSP_041287.
FT   VARIANT      17     17       T -> A (increased risk for Graves
FT                                disease, insulin-dependent diabetes
FT                                mellitus, thyroid-associated orbitopathy,
FT                                systemic lupus erythematosus and
FT                                susceptibility to HBV infection;
FT                                dbSNP:rs231775).
FT                                /FTId=VAR_013577.
FT   CONFLICT     37     37       A -> V (in Ref. 3; ABG85285).
FT   CONFLICT    147    147       T -> A (in Ref. 8; AAA52773).
FT   STRAND       44     47
FT   STRAND       57     60
FT   STRAND       64     66
FT   STRAND       69     73
FT   STRAND       76     79
FT   STRAND       85     89
FT   STRAND      101    103
FT   STRAND      109    113
FT   TURN        121    123
FT   STRAND      125    127
FT   STRAND      129    133
FT   STRAND      135    138
FT   STRAND      147    150
FT   STRAND      156    158
SQ   SEQUENCE   223 AA;  24656 MW;  6F9466FB2E139A5A CRC64;
     MACLGFQRHK AQLNLATRTW PCTLLFFLLF IPVFCKAMHV AQPAVVLASS RGIASFVCEY
     ASPGKATEVR VTVLRQADSQ VTEVCAATYM MGNELTFLDD SICTGTSSGN QVNLTIQGLR
     AMDTGLYICK VELMYPPPYY LGIGNGTQIY VIDPEPCPDS DFLLWILAAV SSGLFFYSFL
     LTAVSLSKML KKRSPLTTGV YVKMPPTEPE CEKQFQPYFI PIN
//
